GRAIL (GRAL)
Developer of Galleri and targeted methylation tools for cancer detection.
Something off on this page? Send us feedback.
Sells Galleri, a physician-ordered blood test for multi-cancer early detection, and provides methylation-based development services to biopharmaceutical partners. Screening drives most revenue; the U.S.-centered business relies on certified laboratory operations, clinical evidence, FDA review, and broader reimbursement.
Markets Galleri, a physician-ordered blood test that screens for a signal shared by multiple cancers and predicts its likely origin. Screening-test sales produce most revenue, while a targeted methylation platform supports research-use classifiers and precision-oncology development services for biopharmaceutical partners. Tests are processed at a CAP-accredited, CLIA-certified laboratory in Durham, North Carolina.
Commercial activity remains centered in the United States, with limited partner-led access in other markets. Execution combines population-scale clinical studies, sequencing, machine-learning classifiers, laboratory automation, and physician-support workflows. Galleri is offered as a laboratory-developed test and is designed to complement recommended single-cancer screening; it is not FDA-approved, and its premarket approval application remains under review. Illumina is the sole supplier of sequencers and certain reagents, and related oncology revenue carries a continuing royalty obligation.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 22, 2026 | Robert W. Baird | Target | Target: $70 | Target: $118 |
| Sep 17, 2026 | UBS | Target | Target: $105 | Target: $84 |
| Sep 17, 2026 | RBC Capital | Initiate | Rating: —Target: — | Target: $84 |
| Sep 9, 2026 | UBS | Initiate | Rating: —Target: $75 | Target: $105 |
| Jul 15, 2026 | Mizuho Securities | Target | Target: $58 | Target: $65 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $861.6M · Total debt $91.3M · Total assets $2.84B · Shareholders' equity $2.54B
- Revenue
- $44.7M
- Operating income
- −$173.8M
- Net income
- −$110.2M
No dividends on record.
| Institutions | 89.48% | 38.40M shares | |
|---|---|---|---|
| 394 holders · as of Jun 30, 2026 | |||
| Insiders | 11.21% | 4.81M shares | |
| 9 holders · as of Aug 31, 2026 | |||
| Adds to | 100.69% | ||
42.92M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 100.69%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Farallon Capital Management LLCInstitution | 9.70% | 4.16M | as of Jun 30, 2026 |
Baker Bros. Advisors LPInstitution | 9.39% | 4.03M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.33% | 3.58M | as of Jun 30, 2026 |
Chun R. DingInsider10 percent owner | 7.70% | 3.31M | filed Jul 3, 2025 |
State Street CorpInstitution | 5.56% | 2.39M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 27, 2026 | Aaron Freidin | officer: Chief Financial Officer | −7,900 | $85.01 |
| Aug 27, 2026 | Joshua J. Ofman | director, officer: Chief Executive Officer | −5,000 | $85.02 |
| Jun 4, 2026 | Andrew John Partridge | officer: Chief Growth Officer | −1,491 | $61.08 |
| Apr 8, 2026 | Joshua J. Ofman | director, officer: President | −61,665 | $49.92 |
| Apr 8, 2026 | Robert P. Ragusa | director, officer: Chief Executive Officer | −123,502 | $49.92 |
- Guardant Health
Blood-based screening and oncology liquid biopsy overlap
- Natera
cfDNA oncology scale in MRD and recurrence monitoring
- Caris Life Sciences
Liquid-biopsy profiling platform with MCED-capable ambitions
- Quest Diagnostics
Scaled lab access and oncology diagnostics compete for channels
- Labcorp
Large diagnostics network with oncology and MRD overlap
- VolitionRx
Smaller epigenetic blood-test platform for cancer detection
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| GRAIL | $110.29 | +2.15% | $4.63B | — | — | 28.0 | +25.7% |
| Guardant Health | $178.36 | +2.58% | $23.33B | — | — | 19.7 | +44.3% |
| Natera | $385.65 | +4.05% | $53.08B | — | — | 19.6 | +37.7% |
| Caris Life Sciences | $32.21 | +5.07% | $8.66B | 85.6 | 127.9 | 8.8 | +45.4% |
| Quest Diagnostics | $232.80 | −4.93% | $27.03B | 26.0 | 20.3 | 2.3 | +10.2% |
| Labcorp | $309.13 | −3.69% | $26.32B | 26.6 | 16.3 | 1.8 | +5.8% |
| VolitionRx | $0.2565 | −3.17% | $2.2M | — | — | 0.9 | −0.3% |
| Median | 26.6 | 20.3 | 5.5 | +24.0% |